KEGG   DRUG: Ombitasvir, paritaprevir and ritonavir
Entry
D10745            Mixture   Drug                                   
Name
Ombitasvir, paritaprevir and ritonavir;
Technivie (TN)
Component
(Ombitasvir hydrate [DR:D10598] | Ombitasvir [DR:D10576]), (Paritaprevir hydrate [DR:D10597] | Paritaprevir [DR:D10580]), Ritonavir [DR:D00427]
Class
Antiviral
 DG03198  Anti-HCV agent
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
 DG02925  CYP3A5 substrate
Metabolizing enzyme inhibitor
 DG02852  CYP3A/CYP3A4 inhibitor
  DG01522  CYP3A4 inhibitor
Transporter substrate
 DG01665  ABCB1 substrate
 DG01913  ABCG2 substrate
 DG02856  SLCO1B1 substrate
 DG02932  SLCO1B3 substrate
Transporter inhibitor
 DG01622  ABCB1 inhibitor
 DG02862  ABCG2 inhibitor
 DG02865  SLCO1B1 inhibitor
 DG02907  SLCO1B3 inhibitor
Remark
ATC code: J05AP53
Efficacy
Antiviral
  Disease
Chronic hepatitis C virus infection [DS:H00413]
Comment
Paritaprevir is an inhibitor and a substrate of P-gp, BCRP and OATP1B1/1B3.
Ombitasvir is metabolized by P-gp.
Ritonavir is an inhibitor and a substrate of P-gp; it is also an inhibitor of CYP3A4 and BCRP.
Target
HCV NS3/4A protease [KO:K22273 K22274]
HCV NS5A [KO:K22275]
HIV protease [KO:K22599]
Metabolism
Enzyme: CYP3A4 [HSA:1576], CYP3A5 [HSA:1577]
Transporter: ABCB1 [HSA:5243], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCG2 [HSA:9429]
Interaction
CYP inhibition: CYP3A4 [HSA:1576]
Transporter inhibition: ABCB1 [HSA:5243], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCG2 [HSA:9429]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP53 Ombitasvir, paritaprevir and ritonavir
      D10745  Ombitasvir, paritaprevir and ritonavir
Drug groups [BR:br08330]
 Antiviral
  DG03198  Anti-HCV agent
   D10745  Ombitasvir, paritaprevir and ritonavir
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10745  Ombitasvir, paritaprevir and ritonavir
  DG02925  CYP3A5 substrate
   D10745  Ombitasvir, paritaprevir and ritonavir
 Metabolizing enzyme inhibitor
  DG02852  CYP3A/CYP3A4 inhibitor
   DG01522  CYP3A4 inhibitor
    D10745  Ombitasvir, paritaprevir and ritonavir
 Transporter substrate
  DG01665  ABCB1 substrate
   D10745  Ombitasvir, paritaprevir and ritonavir
  DG01913  ABCG2 substrate
   D10745  Ombitasvir, paritaprevir and ritonavir
  DG02856  SLCO1B1 substrate
   D10745  Ombitasvir, paritaprevir and ritonavir
  DG02932  SLCO1B3 substrate
   D10745  Ombitasvir, paritaprevir and ritonavir
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   D10745  Ombitasvir, paritaprevir and ritonavir
  DG02862  ABCG2 inhibitor
   D10745  Ombitasvir, paritaprevir and ritonavir
  DG02865  SLCO1B1 inhibitor
   D10745  Ombitasvir, paritaprevir and ritonavir
  DG02907  SLCO1B3 inhibitor
   D10745  Ombitasvir, paritaprevir and ritonavir
Antimicrobials [BR:br08307]
 Antivirals
  Polyprotein cleavage inhibitor
   HCV NS3/4A inhibitor
    D10745  Ombitasvir, paritaprevir and ritonavir
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10745
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10745
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10745
 Drug transporters
  D10745
Other DBs
PubChem: 254741706
ChEBI: 90919
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system